SVB’s collapse is a reminder of how far IP finance still has to travel
Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it
Like many others, the bank held thousands of patents as security for loan deals, but almost certainly had no idea of their value – or lack of it
Marconi's Kasim Alfalahi takes the top spot for Avanci's stellar showing in our countdown of the patent market’s most innovative and influential dealmakers and decision takers
We compiled data from Westfleet Advisors’ annual litigation funding reports to find patent finance shot up by nearly 50% since 2020 – to the benefit of rights holders
The Long Read: It’s no longer all about infringement, write Michelle Avery, Nicole McTernan and Drew Sills of Ocean Tomo. Instead, IP specialists are increasingly being called on in a diverse array of corporate lawsuits
01 December 2021
The deal shows how privacy and silo barriers to the commercialisation of information are being overcome
29 November 2021
Saturday Opinion: After a highly successful IPBC in Seattle earlier this week, it is clear that there has never been a better time to take the value creation gospel to the boardroom
20 November 2021
Brian Hinman, chief commercial officer at Aon IP Solutions, tells IAM how the group facilitates IP-backed funding deals centred on high-quality assets
18 November 2021
The final day of this year’s event in Seattle saw some of the market’s biggest names explain how to get the attention of the c-suite
17 November 2021
Highlights from the plenaries, breakouts and networking sessions as the world’s premier IP business event continues in Seattle
16 November 2021
Delegates talk big ticket investments and speculate on Kathi Vidal’s USPTO Director confirmation hearing in the Senate
15 November 2021
Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum
05 November 2021
The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine
02 November 2021
In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales
01 November 2021
Unlock unlimited access to all IAM content